Abstract:The post hoc analysis presented here aimed to address the influence of endogenous vitamin D in the immunological mechanism underlying effective mite allergoid immunotherapy (AIT). Previously, we have shown that in allergic children, after 12 months of this immunoactive treatment, functionally potentiated memory regulatory T cells are identified. Indeed, AIT is the only known treatment that is able to reshape the detrimental immune response against the allergen into a non-noxious one. Besides, VD is widely considered an immunoregulatory molecule that is endogenously produced and exogenously provided by foods and supplements that might interact with the AIT mechanism, thus affecting its outcome. Therefore, a post hoc analysis of the clinical and immunological data from three different cohorts of allergic patients was performed. One cohort (N = 70) was on a standard symptom-controlling pharmacological treatment, while the other two (N = 60 and N = 35) were treated with AIT for 12 months. In the first cohort, a lower mean endogenous VD level (<22 ng/mL) was observed along with worse symptoms and a greater use of medications. Remarkably, the comparison between two sub-cohorts of patients with a serum VD level above (N = 32) or below (N = 28) a cut-off value set at the mean value (27 ng/mL) revealed that optimal improvement of all clinical and immune parameters was achieved (as expected from effective AIT), irrespective of the VD level. Notably, the third analysis, carried out on one cohort of AIT patients that were also concomitantly taking VD3 as a food supplement (N = 19), was distinguished by an uppermost overall treatment outcome (the amelioration of symptoms, the lowest medication requirements, and a reduction in the total and allergen-specific IgE levels), as well as an increase in the allergen-specific tolerogenic memory T regulatory cells. These findings suggest that the endogenous VD level affects the allergy severity and allergen immunotherapy effectiveness. In addition, VD3 might be investigated as an add-on supplement to obtain the best out of immunotherapy in VD-deficient/-insufficient allergic patients. The immunogenic, but low-allergenic, mite allergoid used as the bioactive agent might have contributed to minimizing the allergic response and highlighting the immunological effects described here.

Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in the Build-up Phase of House Dust Mite-Specific Immunotherapy

Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite

Effect of baseline serum vitamin D level on symptom and medication scores of subcutaneous immunotherapy in children with mite allergy

Induction Of Cd4(+)Cd25(+)Foxp3(+)Il-10(+) T Cells In Hdm-Allergic Asthmatic Children With Or Without Sit

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Sublingual Immunotherapy of Atopic Dermatitis in Mite-Sensitized Patients: a Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study

Immunotherapy for house-dust mite allergy

Vitamin D Role in Childhood Mite Allergy and Allergen Immunotherapy (AIT)

Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients

Effects of Subcutaneous Immunotherapy in Allergic Rhinitis Children Sensitive to Dust Mites.

Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial

Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.

Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy

Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials

A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis

House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma

Topical Vitamin D May Modulate Human Sinonasal Mucosal Responses to House Dust Mite Antigen

Dust mite component Analysis: Identifying key allergens components for effective immunotherapy in allergic rhinitis

Study Effect of Vitamin D on the Immunopathology Responses of the Bronchi in Murine Model of Asthma

Sublingual immunotherapy may be effective in reducing house dust mite allergies in children with atopic dermatitis

A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.